For example, the PARP inhibitor olaparib may be actionable with germline or somatic mutations for BRCA1 or BRCA2 in advanced and metastatic ovarian cancers [25,26] and pembrolizumab might be actionable in PD-L1-positive cases of ovarian cancer progression or those with microsatellite instability in advanced and metastatic ovarian cancers [27,28,29]. This evidence concerns the gene BRCA2 and ovarian carcinoma.